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Introduction
Thymic carcinomas are rare epithelial tumors of the thymus with limited data to guide management decisions. 1 Thymic carcinomas are the most aggressive thymic tumor subtype. 2 Surgery is considered the cornerstone of management and typically the first step in treatment. 3, 4 Adjuvant therapies such as radiation therapy (RT) and chemotherapy are often used to decrease the risk for recurrence. [5] [6] [7] [8] [9] Given the rarity of thymic epithelial tumors and paucity of prospective clinical trials, variability exists in practices for managing them.
The International Thymic Malignancies Interest Group (ITMIG) was established to increase collaborative efforts focused on these tumors and develop management guidelines to enhance uniformity in treatment of these tumors. The Thymic Carcinoma Working Group (TCWG) is composed of a multidisciplinary group of ITMIG clinicians who meet regularly to identify ways to standardize and advance the work-up and management of thymic carcinoma. We surveyed ITMIG clinicians to identify areas of agreement and variability in current clinical practice related to management of thymic carcinomas.
Methods
A 16-question electronic survey was designed and approved by the members of the TCWG. All 565 ITMIG members were identified and invited to participate. Questions were directed at demographics and initial clinical management of thymic carcinoma ( Table 1) .
The survey was conducted from December 9, 2013, to January 20, 2014. By grouping answers together, general agreement was determined by greater than 60% concordance.
Areas of controversy were discussed with the TCWG and consensus was achieved, when possible, before the manuscript was prepared.
Results
A total of 100 ITMIG members responded. Table 2 lists the demographic information of the survey responders. Responses are depicted in Figure 1 .
Areas of General Agreement and Controversy
Areas of General Agreement. The following areas of general agreement were identified: (1) the treatment course for stage IVA thymic carcinoma with a limited number of left-sided pleural nodules (question 4), with 87% of responders recommending multimodality therapy, including surgery; (2) the surgical management of stage IVA disease with multiple (>5) pleural nodules (question 5), with 60% of responders recommending thymectomy with or without pleurectomy/decortication; (3) the treatment course for resectable disease with two biopsy-proven cervical lymph nodes (question 7), with 69% of responders recommending multimodality therapy including surgery; (4) the treatment of locally recurrent disease (question 9), with 75% of responders recommending multimodality therapy including surgery; (5) the treatment course for unresectable disease due to great vessel invasion (question 10), with 71% of responders recommending definitive chemoradiation; (6) the acceptable technique for adjuvant radiotherapy (question 11), with 93% of responders choosing some form of three-dimensional planned radiation; and (7) the acceptable dose of RT after an R1 resection (question 12), with 73% of responders choosing 50 to 60 Gy.
Areas of Controversy. The following areas of controversy were identified: (1) the need for histologic confirmation of the pathologic diagnosis before a total thymectomy (question 1), with 54% of responders recommending upfront total thymectomy, 36% recommending a core biopsy, and 10% recommending an alternative form of biopsy; (2) the role of adjuvant therapy after an R0 resection of a Masaoka stage II thymic carcinoma (question 2), with 51% of responders recommending observation, 25% recommending adjuvant RT alone, 13% recommending adjuvant RT and chemotherapy, and 11% recommending adjuvant chemotherapy alone; (3) the role of adjuvant therapy after an R0 resection of a Masaoka stage III thymic carcinoma (question 3), with 42% of responders recommending adjuvant RT alone, 34% recommending adjuvant RT and chemotherapy, 14% recommending observation, and 10% recommending adjuvant chemotherapy alone; (4) the preferred first-line chemotherapy for stage IVB thymic carcinoma (question 6), with 42% of responders recommending cisplatin/ doxorubicin/cyclophosphamide, 23% recommending a platinum/taxane combination, 19% recommending cisplatin/etoposide, and 16% recommending doxorubicin/cisplatin/vincristine/cyclophosphamide; and (5) the recommended treatment course for disease with invasion into the great vessels, pericardium, and lungs bilaterally (question 8), with 46% of responders recommending definitive chemoradiation, 39% recommending multimodality therapy with surgery, and 15% recommending chemotherapy alone.
Analysis by Specialty
Upon further review of the results by specialty, some generalizations were noted. Surgeons were more likely to recommend surgical management for stage IVA disease with multiple (>5) pleural nodules (question 5: 80% versus 48% versus 62%) or involvement of cervical lymph nodes (question 7: 79% versus 55% versus 34%).
Discussion
We have presented the results of a questionnaire that provides a cross-sectional assessment of the management patterns of 100 ITMIG members, a group of A 50-year-old patient presents with a 5 Â 6-cm anterior mediastinal mass with invasion of the mediastinal fat but not the lungs, pericardium, heart, or great vessels. On examination, two cervical (jugular and supraclavicular) lymph nodes are identified and found to be biopsy-proven thymic carcinoma. What is your recommended treatment course?
A. Chemotherapy only B. Thymectomy and lymph node dissection alone C. Neoadjuvant chemotherapy followed by thymectomy and lymph node dissection D. Neoadjuvant concurrent chemotherapy and RT followed by thymectomy and lymph node dissection E. Thymectomy and lymph node dissection with neoadjuvant or adjuvant chemotherapy F. Neoadjuvant chemotherapy, thymectomy, and lymph node dissection followed by postoperative RT G. Definitive concurrent chemotherapy and RT 8
A 65-year-old patient presents with a 13 x 15-cm thymic carcinoma in the anterior mediastinum with invasion of the great vessels, pericardium, and lungs bilaterally. What is your next recommended treatment step?
A. Chemotherapy only B. Neoadjuvant chemotherapy followed by surgery C. Neoadjuvant concurrent chemotherapy and RT followed by surgery D. Definitive chemotherapy and RT (sequential or concurrent) E. RT only (continued)
April 2017 Thymic Carcinoma Management Surveyphysicians with various specialties and a particular clinical and scientific interest and expertise in these rare tumors. Although there was agreement in some areas, clinical practice varies. The areas of controversy highlight a clear need for collaborative research to identify optimal evaluation and treatment strategies. The areas of controversy identified from this survey were discussed by the TCWG, and consensus across various disciplines was sought whenever possible.
Diagnostic Work-up
The group discussed the need for pathologic diagnosis of thymic carcinoma before surgical resection. The consensus was that if patients require neoadjuvant therapy or if there is clinical or radiographic concern for lymphoma, germ cell tumor, or other malignancy that is not typically managed with upfront surgery, then a core biopsy is indicated.
Surgical Management
Surgery is generally considered the cornerstone of treatment for patients with resectable thymic malignancies. 3, 4 In patients with localized disease, the goal of surgery is curative. In patients with stage IVA thymic carcinomas, however, generally the goal is prolonged disease-free survival. There was general agreement on the need for multimodality therapy with surgery for patients with stage IVA thymic carcinoma with pleural nodules, involved cervical lymph nodes, or recurrent CT, computed tomography; RT, radiation therapy; 2D, two-dimensional; 3D, three-dimensional. Figure 1 . Survey responses by question. RT, radiation therapy; Gy, Gray.
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Thymic Carcinoma Management Survey disease. It is important to note, however, that most of the responders were surgeons. The decision regarding the role of surgical management of locally advanced thymic carcinoma has to be weighed against the risks of the invasive procedure. The differing responses seen regarding the treatment course for patients with invasion into the great vessels, pericardium, and lungs bilaterally was thought to be related to differences in what was considered "resectable" by responders. Typically, invasion of the pericardium and lung does not preclude surgical resection and can be managed by pericardial resection and/or lung resection. Additionally, if patients have invasion of certain blood vessel (e.g., the superior vena cava or innominate vein), they may still be resectable. Because surgery is the main treatment modality in this disease, every attempt should be made to achieve an R0 resection.
A clinical vignette, which clearly stated that the patient was unresectable on account of great vessel invasion, resulted in agreement that the patient should be treated with definitive chemoradiation. This topic was discussed by the group, and it was mentioned that there is limited data suggesting a potential role for debulking surgery in thymic carcinoma. 2, 10, 11 A recent large retrospective Japanese Nationwide Database study provided support that maximal debulking surgery might be beneficial in these patients. 12 Because of the retrospective nature of that study, however, there is likely significant patient selection bias.
RT
The group discussed the role of adjuvant therapy in patients with Masaoka stage II and III disease. Since the survey was conducted, there have been three publications demonstrating the benefit of adjuvant RT in large cohorts with completely resected thymic carcinoma. 5, 7, 9 Adjuvant RT demonstrated an overall survival benefit. 5, 9, 13 Because of these recent data, the group recommended the use of adjuvant RT in patients with Masaoka stage II and III disease. The role of adjuvant RT in patients with completely resected Masaoka stage I thymic carcinoma requires further evaluation.
Chemotherapy
The role of adjuvant chemotherapy is less clear in patients with Masaoka stage II and III disease. The options for first-line chemotherapy in patients with inoperable disease were discussed. The regimens of cisplatin/ doxorubicin/cyclophosphamide and etoposide/cisplatin were generally considered preferred first-line regimens for malignant thymoma. In thymic carcinoma, recent data from phase II trials evaluating carboplatin/paclitaxel and capecitabine/gemcitabine have demonstrated favorable results. 6, 8 The consensus from the TCWG was that there are insufficient data to favor one chemotherapy regimen over another and that more data are required to determine the optimal choice for first-line chemotherapy in patients with unresectable disease.
The role of molecular targeted therapy in the treatment of unresectable thymic carcinoma has been evaluated in phase II clinical trials. 14, 15 Further efforts are needed to identify additional molecular targets in thymic carcinoma and evaluate the role of immunotherapy.
Conclusion
In conclusion, the aforementioned results from a survey of providers specializing in thymic malignancies provide guidance for the treatment of patients with thymic carcinoma. The survey is limited by a small number of respondents, most of whom are surgeons. Despite this, areas of agreement were determined, and the areas of controversy were discussed within the TCWG to derive consensus. These results highlight the need for collaborative research to identify optimal evaluation and treatment strategies, especially for management of locally advanced thymic carcinomas. The TCWG is currently working on multiple projects, including prospective databases, immunotherapy trials, and genomic analyses, among others, to enhance clinical management and improve outcomes of patients with thymic carcinoma. Given the need for multimodality therapy in many cases, a multidisciplinary discussion of the management of patients with thymic carcinoma is critical.
